Selective Endothelin-A Receptor Antagonist MOA

Hybrid was selected by Abbott Laboratories and their agency Vox Medica, Inc. to create a MOA animation centered on Abbott’s development of a new cancer-specific, oral selective endothelin-A receptor antagonist (SERA™).

This 6-minute animation was produced by Hybrid to help expand viewers’ understanding of:

• Hormone-refractory prostate cancer

• The Endothelin Axis

• The impact of this new receptor antagonist on the endothelin-A pathway

The project was produced and set up in a way that enabled our clients to select scenes from the MOA and re-render them for use in their large-scale booth display panels at ASCO.

This sequence on bone metastasis is a segment from the animation.